Menu
Recruiting NCT06525831

Rein 3D PRINT MECHANICS

No phase Interventional Kidney Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: MR-elastography exam, Ultrasound exam.
Who it may be relevant to
Registry conditions: Kidney Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Multimodal Imaging of the Biomechanical Properties of Kidney Tumors: Feasibility, Inter-modality Correspondence and Diagnostic Value

Overview

The goal of this innovative project is to evaluate the correspondence between several imaging modalities for characterizing the elasticity of healthy and pathological renal tissue which could help improve the realism of 3D prints used by urological surgeons and allow the identification of new, complementary imaging biomarkers. The main objective is to develop a predictive model of the biomechanical properties of normal and pathological kidney tissue, as assessed by the reference method (Magnetic Resonance (MR)-elastography).

Detailed description

Medical imaging plays a key role in the diagnostic and therapeutic management of renal cell carcinomas. It can be used to confirm the presence of a tumor, localize it, suggest malignancy or even histological subtype, guide sampling, perform TNM staging, assist in surgical scheduling, monitor therapeutic efficacy in the event of systemic treatment, guide ablathermy procedures and look for relapses after curative treatments have ended. Imaging of kidney tumors relies on three complementary imaging modalities: ultrasound (US), Computed Tomography based on X-ray absorption (CT-scan) and magnetic resonance imaging (MRI). The most commonly performed examination remains the CT scan, which is used to print 3D models. However, the correlation between renal parenchyma densities and renal tumors (before and during the scan acquisition times after injection) and elasticity parameters measured by US and MRI has never been explored.

This trial aim to evaluate the correspondence between several imaging modalities for characterizing the elasticity of healthy and pathological kidney tissue. It will also improve the realism of 3D models used by surgeons, and identify new complementary imaging biomarkers.

To achieve this aim, 50 patients will undergo DWI -elastography (Diffusion Weigthed Imaging-elastography) and MR-elastography sequences, as well as an US before the surgery. After surgery, a fragment of the resected specimen will be used to perform mechanical tests to determine the real hardness of the tissue.

Interventions

  • Diagnostic test MR-elastography exam
    Imaging acquisition
  • Diagnostic test Ultrasound exam
    Imaging acquisition

Primary outcome measures

  • Measurement of the root mean square error (RMSE) [Time frame: Between Day 0 and Month 4]
Secondary outcome measures (9)
  • Measure of Spearman's rho [Time frame: Between Day 0 and Month 4]
  • Measure of the qualitative assessment [Time frame: Between Day 0 and Month 4]
  • Measure of the contrast [Time frame: Between Day 0 and Month 4]
  • Measure of the noise [Time frame: Between Day 0 and Month 4]
  • Identification of imaging faisability limiting factors [Time frame: Between Day 0 and Month 4]
  • Evaluation of imaging repetabiliy limiting factors [Time frame: Between Day 0 and Month 4]
  • identification of decorrelation situations and potential bias between biomechanical properties obtained by hardness measurements in the different imaging modalities [Time frame: Between Day 0 and Month 4]
  • Carry out associations between histological categorical variables and numerical elasticity variables [Time frame: Between Day 0 and Month 4]
  • Measure of the accuracy [Time frame: Between Day 0 and Month 4]

Eligibility criteria

Inclusion criteria

  • Adult patients (≥ 18 years of age)
  • Scheduled for surgical management with nephrectomy for kidney tumor in the urology department of Bordeaux University Hospital
  • CT scan available or scheduled for surgery
  • Consent expressed for integration of the UroCCR database
  • Expressed consent for participation in the Rein 3D Print Mechanics study
  • Patients affiliated or benefiting from social security system

Exclusion criteria

  • \- Pregnant or breast-feeding women
  • Contraindication to MRI (Magnetic Resonance Imaging)
  • Contraindication to injection of gadoline contrast agents
  • Biopsy performed within 15 days prior to MRI, CT and ultrasound scans (risk of artifactual alteration, via iatrogenic hemorrhagic changes, of the biomechanical properties of the renal tumor and parenchyma).
  • Presence of thoracolumbar arthrodesis material
  • Obese patient (body mass index ≥ 30 kg/m²)
  • Cystic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) < 2 cm
  • Necrotic renal tumors with solid component (corresponding to either parietal thickening or tumor bud) < 2 cm
  • Ascites
  • Person under legal protection
  • Difficulty understanding and expressing in French

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

France · 1 center
  • CHU de Bordeaux — Bordeaux

Publications

  • Ronca M, Conforti P, Crombe A, Jaffredo M, Ricard S, Colin T, Yacoub M, Le Bras Y, Bernhard JC, Margue G, Fourage-Jambon E. Multimodal imaging to analyze the biomechanical properties of kidney tumors, evaluating feasibility, inter-modality correspondence, and diagnostic value (UroCCR-115). PLoS One. 2026 Jul 8;21(7):e0351477. doi: 10.1371/journal.pone.0351477. eCollection 2026. PMID 42418537

Identifiers

NCT: NCT06525831 · CHUBX 2022/11

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗